Emergent BioSolutions Q4 loss narrows 37% to $31.3M; FY24 revenue $1.04B; guides FY25 EBITDA $150-200M

Emergent BioSolutions Inc.

Q4 2024 total revenue $194.7M, down 30% YoY; net loss $31.3M vs. $49.5M loss in Q4 2023.
FY 2024 total revenue $1.04B (flat YoY); net loss $190.6M vs. $760.5M loss; adjusted EBITDA $183.1M vs. ($22.3M) loss.
FY 2025 guidance: revenue $750-850M; adjusted EBITDA $150-200M; segment adjusted gross margin 48-51%.
NARCAN sales fell 41% in Q4; Smallpox MCM sales surged 565% on ACAM2000 exports; Anthrax MCM down 71%.
Appointed CEO Joseph Papa; received ~$550M medical countermeasure awards; FDA approved ACAM2000 for mpox prevention.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.